Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy
(2020) In Leukemia Research 90.- Abstract
Several studies have now shown that chronic myeloid leukaemia (CML) patients in deep molecular remission may discontinue tyrosine kinase inhibitor (TKI) treatment with a treatment free remission (TFR) rate of approximately 40–60 %. Some factors influencing the possibility of TFR have been described but better tools are needed for individual prediction of long-term TFR. Herein, two multiplex panels were utilised to analyse a total of 162 different plasma proteins from 56 patients included in the TKI stopping trial EURO-SKI (Saussele et al., 2018). The purpose was to identify possible plasma protein markers for prediction of successful TKI discontinuation and to evaluate effects of TKI discontinuation on plasma protein profiles. No... (More)
Several studies have now shown that chronic myeloid leukaemia (CML) patients in deep molecular remission may discontinue tyrosine kinase inhibitor (TKI) treatment with a treatment free remission (TFR) rate of approximately 40–60 %. Some factors influencing the possibility of TFR have been described but better tools are needed for individual prediction of long-term TFR. Herein, two multiplex panels were utilised to analyse a total of 162 different plasma proteins from 56 patients included in the TKI stopping trial EURO-SKI (Saussele et al., 2018). The purpose was to identify possible plasma protein markers for prediction of successful TKI discontinuation and to evaluate effects of TKI discontinuation on plasma protein profiles. No protein biomarkers sampled before TKI discontinuation could separate relapse cases from non-relapse cases but some plasma proteins differed between patients who relapsed and those who remained in TFR when followed over time after TKI cessation. In conclusion, the plasma protein markers in this study could not predict relapse after TKI discontinuation but may be of use to understand the mechanisms involved in maintenance of TFR.
(Less)
- author
- Söderlund, Stina ; Persson, Inger ; Ilander, Mette ; Guilhot, Joëlle ; Hjorth-Hansen, Henrik ; Koskenvesa, Perttu ; Richter, Johan LU ; Saussele, Susanne ; Mustjoki, Satu and Olsson-Strömberg, Ulla
- publishing date
- 2020
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Chronic myeloid leukemia, Immunology, Proteomics, Treatment free remission, Tyrosine kinase inhibitor
- in
- Leukemia Research
- volume
- 90
- article number
- 106310
- publisher
- Elsevier
- external identifiers
-
- pmid:32058176
- scopus:85079066669
- ISSN
- 0145-2126
- DOI
- 10.1016/j.leukres.2020.106310
- language
- English
- LU publication?
- no
- id
- e10e95b0-4b20-4095-9690-aa8b13694edb
- date added to LUP
- 2020-02-19 15:45:38
- date last changed
- 2024-04-03 02:32:31
@article{e10e95b0-4b20-4095-9690-aa8b13694edb,
abstract = {{<p>Several studies have now shown that chronic myeloid leukaemia (CML) patients in deep molecular remission may discontinue tyrosine kinase inhibitor (TKI) treatment with a treatment free remission (TFR) rate of approximately 40–60 %. Some factors influencing the possibility of TFR have been described but better tools are needed for individual prediction of long-term TFR. Herein, two multiplex panels were utilised to analyse a total of 162 different plasma proteins from 56 patients included in the TKI stopping trial EURO-SKI (Saussele et al., 2018). The purpose was to identify possible plasma protein markers for prediction of successful TKI discontinuation and to evaluate effects of TKI discontinuation on plasma protein profiles. No protein biomarkers sampled before TKI discontinuation could separate relapse cases from non-relapse cases but some plasma proteins differed between patients who relapsed and those who remained in TFR when followed over time after TKI cessation. In conclusion, the plasma protein markers in this study could not predict relapse after TKI discontinuation but may be of use to understand the mechanisms involved in maintenance of TFR.</p>}},
author = {{Söderlund, Stina and Persson, Inger and Ilander, Mette and Guilhot, Joëlle and Hjorth-Hansen, Henrik and Koskenvesa, Perttu and Richter, Johan and Saussele, Susanne and Mustjoki, Satu and Olsson-Strömberg, Ulla}},
issn = {{0145-2126}},
keywords = {{Chronic myeloid leukemia; Immunology; Proteomics; Treatment free remission; Tyrosine kinase inhibitor}},
language = {{eng}},
publisher = {{Elsevier}},
series = {{Leukemia Research}},
title = {{Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy}},
url = {{http://dx.doi.org/10.1016/j.leukres.2020.106310}},
doi = {{10.1016/j.leukres.2020.106310}},
volume = {{90}},
year = {{2020}},
}